We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Critical Care Diagnostics Market Worth USD 1.29 Billion By 2024

By LabMedica International staff writers
Posted on 16 Aug 2016
The global critical care diagnostics (CCD) market will grow at a lucrative rate over the next few years to reach USD 1.29 billion by 2024, driven by the rapid awareness and acknowledgment of these tests by physicians and patients, rise in geriatric population and chronic health conditions, use of telehealth services in remote areas, and technological advancements. More...
However, increased cost of molecular diagnostics and shortage of skilled labor to handle new platforms are expected to hinder the industry’s growth.

These are the findings of Grand View Research, Inc. (San Francisco, CA, USA), a market research and consulting company, which estimates the global CCD market size in 2015 to be USD 837.6 million.

CCD tests, such as the nucleic acid amplification test, allow clinicians to detect and identify organisms rapidly and accurately, as well as guide clinicians who wish to quickly commence treatment using the right antimicrobial therapy without any delay and terminate the use of avoidable drugs.

By test type, the CCD market is categorized into routine and special chemistry, flow cytometry, hematology, immunoproteins, microbial and infectious diseases, coagulation testing, and others. In 2015, the immunoproteins segment accounted for the largest share in terms of value, due to an increase in the demand for rapid and accurate early diagnosis, as well as the ability to reduce the recovery time of patients. By the end-user, the CCD market is categorized into operation rooms, emergency rooms, and ICUs.

The growth of the CCD market is driven mainly by factors, such as clinical chemistry, flow cytometry tests, and coagulation tests, among others. Growing awareness among patients for better healthcare options and increase in knowledge of target therapy among physicians has led to a higher demand for CCD tests. Moreover, the increasing adoption of telehealth and rising awareness of advanced diagnostics tools has also influenced the growth of the CCD market.

Over the 2013-2024 period, microbiology and infectious tests along with immunoproteins assays are estimated to drive the CCD market growth, with the microbial and infectious diseases test diagnostics segment likely to record the highest CAGR of over 5%. With approximately 58% of patients getting admitted in emergency rooms and nearly 20% of acute-care patients in ICUs, the emergency rooms segment is expected to record the highest growth rate over the same period.

As of 2015, the North American CCD market held the largest share of the global market, followed by Europe. Going forward, the Asia Pacific region is estimated to record the highest growth rate, with a CAGR of around 9.1% over 2013-2024, led by a large geriatric population, increasing chronic diseases, growth in intensive care specialized hospitals in India, and improving healthcare services and infrastructures across rural areas.

Related Links:
Grand View Research



Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Influenza Virus Test
NovaLisa Influenza Virus B IgM ELISA
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.